Rallybio Stock Drops: 2025 Study Plans Announced

Rallybio Corporation plunged 2.39% in after-hours trading, following the company's announcement of plans to initiate confirmatory pharmacokinetics and pharmacodynamics studies for RLYB116 in the second quarter of 2025, with data expected to be released in the third and fourth quarters of the same year. The company's stock had previously surged 35.87% to $0.40 during Wednesday's trading, reaching a market capitalization of $16.6 million.